| 货号 | 13627-500mg |
| 描述 | Lansoprazole is a proton pump inhibitor that inactivates the hydrogen/potassium-stimulated ATPase pumps in parietal cells, thus inhibiting gastric acid secretion and increasing intragastric pH.1 A substituted benzimidazole, it binds covalently to proton pumps, providing complete and prolonged inhibition of acid secretion. Pharmacokinetic properties include a time of maximal plasma concentration after oral administration (Tmax) of 1.2 - 2.1 hours, and an oral bioavailability of 80-90%.2,3,4 Lansoprazole is metabolized by several human cytochrome P450s, most prominently by CYP2C19 and CYP3A4.5,3 |
| 别名 | AG-1749;Prevacid; |
| 供应商 | Cayman |
| 应用文献 | |
| 1.Schubert, M.L. Pharmacotherapy for acid/peptic disorders. Yale Journal of Biology and Medicine 69, 197-201 (1996). 2.Richardson, P.,Hawkey, C.J., and Stack, W.A. Proton pump inhibitors. Pharmacology and rationale for use in gastrointestinal disorders. Drugs 56(3), 307-335 (1998). 3.Klotz, U. Pharmacokinetic considerations in the eradication of Helicobacter pylori. Clinical Pharmacokinetics 38(3), 243-270 (2000). 4.Shi, S., and Klotz, U. Proton pump inhibitors: An update of their clinical use and pharmacokinetics. Eur. J. Clin. Pharmacol. 64, 935-951 (2008). 5.Meyer, U.A. Interaction of proton pump inhibitors with cytochromes P450: Consequences for drug interactions. Yale Journal of Biology and Medicine 69, 203-209 (1996). | |
| 运输条件 | Room temperature in continental US; may vary elsewhere |
| 存放说明 | -20 |
| 纯度 | ≥98% |
| 计算分子量 | 369.4 |
| 分子式 | C16H14F3N3O2S |
| CAS号 | 103577-45-3 |
| 稳定性 | ≥ 2 years |
| 本官网所有报价均为常温或者蓝冰运输价格，如有产品需要干冰运输，需另外加收干冰运输费。 |